Summary Luc Therapeutics Inc (Luc), formerly Mnemosyne Pharmaceuticals, Inc. is a drug development company that develops medicines for serious psychiatric diseases. The company's products include NR2B positive allosteric modulators, NR2A negative allosteric modulators, and NR2B negative allosteric modulators. Its NR2A negative allosteric modulators are used to modify disease course and treat symptoms of Rett Syndrome and other autism disorders. Luc also develops subunit-selective NMDA receptor modulators which increase/decrease the activity of NR2 subtypes. The company's products are used in the therapeutic areas of schizophrenia, other cognitive and neuropsychiatric disorders. Its SNRMs are also used to treat cognitive dysfunction underlying neuropsychiatric disorders. Luc is headquartered in Cambridge, Massachusetts, the US. Luc Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on... Research Beam Model: Research Beam Product ID: 2032785 250 USD New
Luc Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
 
 

Luc Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • Category : Company Profiles
  • Published On : August   2017
  • Pages : 20
  • Publisher : GlobalData
 
 
 
Summary

Luc Therapeutics Inc (Luc), formerly Mnemosyne Pharmaceuticals, Inc. is a drug development company that develops medicines for serious psychiatric diseases. The company's products include NR2B positive allosteric modulators, NR2A negative allosteric modulators, and NR2B negative allosteric modulators. Its NR2A negative allosteric modulators are used to modify disease course and treat symptoms of Rett Syndrome and other autism disorders. Luc also develops subunit-selective NMDA receptor modulators which increase/decrease the activity of NR2 subtypes. The company's products are used in the therapeutic areas of schizophrenia, other cognitive and neuropsychiatric disorders. Its SNRMs are also used to treat cognitive dysfunction underlying neuropsychiatric disorders. Luc is headquartered in Cambridge, Massachusetts, the US.

Luc Therapeutics Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Luc Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Luc Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Luc Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Luc Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Luc Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Luc Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Mnemosyne Pharma Raises US$6 Million In Extended Series A Financing 10
Mnemosyne Pharma Raises US$5.4 Million In Series A Financing 11
Mnemosyne Pharma Secures Funding In Second Round Of Seed Financing 12
Partnerships 13
Jubilant BioSys Enters Into Co-Development Agreement With Mnemosyne Pharma 13
Merger 14
Ataxia to Merge with Luc Therapeutics 14
Licensing Agreements 15
Luc Therapeutics Enters into Licensing Agreement with Novartis 15
Luc Therapeutics Inc - Key Competitors 16
Luc Therapeutics Inc - Key Employees 17
Luc Therapeutics Inc - Locations And Subsidiaries 18
Head Office 18
Recent Developments 19
Clinical Trials 19
Aug 14, 2017: Saniona's partner, Luc Therapeutics, nominates clinical candidate and initiates preclinical development in joint Ataxia program 19
Appendix 20
Methodology 20
About GlobalData 20
Contact Us 20
Disclaimer 20

List of Tables
Luc Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts 2
Luc Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Luc Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Luc Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Luc Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Luc Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Mnemosyne Pharma Raises US$6 Million In Extended Series A Financing 10
Mnemosyne Pharma Raises US$5.4 Million In Series A Financing 11
Mnemosyne Pharma Secures Funding In Second Round Of Seed Financing 12
Jubilant BioSys Enters Into Co-Development Agreement With Mnemosyne Pharma 13
Ataxia to Merge with Luc Therapeutics 14
Luc Therapeutics Enters into Licensing Agreement with Novartis 15
Luc Therapeutics Inc, Key Competitors 16
Luc Therapeutics Inc, Key Employees 17
List of Figures
Luc Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
Luc Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
Luc Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
Luc Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
Luc Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Luc Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
Luc Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Luc Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter